These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Limited potential for mosquito transmission of genetically engineered, live-attenuated western equine encephalitis virus vaccine candidates. Turell MJ; O'Guinn ML; Parker MD Am J Trop Med Hyg; 2003 Feb; 68(2):218-21. PubMed ID: 12641414 [TBL] [Abstract][Full Text] [Related]
31. The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83. Kinney RM; Johnson BJ; Welch JB; Tsuchiya KR; Trent DW Virology; 1989 May; 170(1):19-30. PubMed ID: 2524126 [TBL] [Abstract][Full Text] [Related]
32. Role of interferon and interferon regulatory factors in early protection against Venezuelan equine encephalitis virus infection. Grieder FB; Vogel SN Virology; 1999 Apr; 257(1):106-18. PubMed ID: 10208925 [TBL] [Abstract][Full Text] [Related]
33. Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates. Fine DL; Roberts BA; Terpening SJ; Mott J; Vasconcelos D; House RV Vaccine; 2008 Jun; 26(27-28):3497-506. PubMed ID: 18508163 [TBL] [Abstract][Full Text] [Related]
34. Virulent and attenuated mutant Venezuelan equine encephalitis virus show marked differences in replication in infection in murine macrophages. Grieder FB; Nguyen HT Microb Pathog; 1996 Aug; 21(2):85-95. PubMed ID: 8844652 [TBL] [Abstract][Full Text] [Related]
35. Molecular determinants of alphavirus neurovirulence: nucleotide and deduced protein sequence changes during attenuation of Venezuelan equine encephalitis virus. Johnson BJ; Kinney RM; Kost CL; Trent DW J Gen Virol; 1986 Sep; 67 ( Pt 9)():1951-60. PubMed ID: 3755750 [TBL] [Abstract][Full Text] [Related]
36. Comparative neurovirulence and tissue tropism of wild-type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H/HeN and BALB/c mice. Steele KE; Davis KJ; Stephan K; Kell W; Vogel P; Hart MK Vet Pathol; 1998 Sep; 35(5):386-97. PubMed ID: 9754544 [TBL] [Abstract][Full Text] [Related]
38. Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses. Fine DL; Roberts BA; Teehee ML; Terpening SJ; Kelly CL; Raetz JL; Baker DC; Powers AM; Bowen RA Vaccine; 2007 Feb; 25(10):1868-76. PubMed ID: 17240002 [TBL] [Abstract][Full Text] [Related]
39. Localization of a protective epitope on a Venezuelan equine encephalomyelitis (VEE) virus peptide that protects mice from both epizootic and enzootic VEE virus challenge and is immunogenic in horses. Hunt AR; Roehrig JT Vaccine; 1995 Feb; 13(3):281-8. PubMed ID: 7543231 [TBL] [Abstract][Full Text] [Related]
40. Association of Venezuelan equine encephalitis virus subtype IE with two equine epizootics in Mexico. Oberste MS; Fraire M; Navarro R; Zepeda C; Zarate ML; Ludwig GV; Kondig JF; Weaver SC; Smith JF; Rico-Hesse R Am J Trop Med Hyg; 1998 Jul; 59(1):100-7. PubMed ID: 9684636 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]